Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) announced that Founder, President and CEO David Hung and CFO Philippe Sauvage will join a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:55 a.m. ET in New York.
A live webcast and 90-day archive will be available on the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – NUVB
In the May 28 session, NUVB gained 0.21%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.9% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Manufacturing partnership | Positive | -1.3% | Thermo Fisher collaboration for U.S.-based IBTROZI manufacturing and tech transfer. |
| May 06 | Regulatory/clinical update | Positive | +4.3% | FDA acceptance of supplemental NDA for IBTROZI with updated duration of response. |
| May 05 | Investor conferences | Neutral | +4.3% | Announcement of participation in multiple investor conferences with webcasts available. |
| May 04 | Earnings and update | Positive | +9.5% | Q1 2026 financial results with IBTROZI revenue, strong cash balance, and clinical updates. |
| Apr 27 | Guideline inclusion | Positive | -6.8% | NCCN adds taletrectinib (IBTROZI) to CNS cancer guidelines for ROS1+ NSCLC with brain mets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive and clinical milestones often saw positive price reactions, but there are notable divergences where strong clinical or guideline updates were followed by declines.
Over the past months, NUVB reported several key milestones, including Q1 2026 earnings with revenue growth and net income on May 4, FDA acceptance of a supplemental NDA for IBTROZI with a January 4, 2027 target action date, and NCCN guideline inclusion for CNS cancers on April 24, 2026. Some of these positive updates aligned with strong gains (earnings, sNDA), while others, like the NCCN guideline addition and a Thermo Fisher manufacturing collaboration, coincided with same-day declines, showing mixed market responses to good news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following the event.
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI ®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-present-at-the-jefferies-global-healthcare-conference-302783463.html
SOURCE Nuvation Bio Inc.